Compare BIVI & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIVI | ALUR |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 15.4M |
| IPO Year | N/A | N/A |
| Metric | BIVI | ALUR |
|---|---|---|
| Price | $1.55 | $1.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 71.9K | ★ 506.0K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.25 | $1.02 |
| 52 Week High | $30.90 | $16.81 |
| Indicator | BIVI | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 54.10 |
| Support Level | $1.45 | $1.37 |
| Resistance Level | $1.70 | $1.75 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 60.36 | 87.55 |
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.